Point72 Hong Kong’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Point72 Hong Kong’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-473	Closed	-$6K	–	2490
2022 Q1	$6K	Buy	473 +102	+27%	+$1.82K	﹤0.01%	1667
2021 Q4	$12K	Sell	371 -335	-47%	-$13.6K	﹤0.01%	1619
2021 Q3	$32K	Buy	706 +443	+168%	+$21.6K	﹤0.01%	1617
2021 Q2	$14K	Buy	263 +23	+10%	+$1.36K	﹤0.01%	1695
2021 Q1	$18K	Buy	240 +82	+52%	+$8.52K	﹤0.01%	1499
2020 Q4	$17K	Sell	158 -114	-42%	-$10.4K	﹤0.01%	1461
2020 Q3	$24K	Buy	+272	New	+$30.9K	﹤0.01%	838
2017 Q4	–	Sell	-19	Closed	-$3K	–	1136
2017 Q3	$3K	Buy	+19	New	+$3.57K	﹤0.01%	626

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Hong Kong's SYRS Position: Q2 2022 in Review

Point72 Hong Kong sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 473 shares — an estimated $6K sold.

Point72 Hong Kong first reported a position in SYRS in Q3 2017 and held it in 8 quarters. The position peaked at $32K in Q3 2021. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Point72 Hong Kong reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Point72 Hong Kong sold 473 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $6K.
Point72 Hong Kong first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 8 quarters.
Point72 Hong Kong's Syros Pharmaceuticals, Inc. Common Stock position peaked at $32K in Q3 2021.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.